{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T18:04:45Z","timestamp":1783965885647,"version":"3.55.0"},"reference-count":6,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1093\/ejhf\/xuag200","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T11:51:16Z","timestamp":1783684276000},"source":"Crossref","is-referenced-by-count":0,"title":["Serum transthyretin as a staging biomarker in ATTR cardiomyopathy: promise, limitations, and the path forward"],"prefix":"10.1093","author":[{"given":"Valentina","family":"Allegro","sequence":"first","affiliation":[{"name":"Center for Diagnosis and Treatment of Cardiomyopathies, Cardiovascular Department, Azienda Sanitaria Universitaria Giuliano-Isontina (ASUGI) and University of Trieste , Via P. Valdoni 7, Trieste 34100 ,","place":["Italy"]},{"name":"European Reference Network for Rare, Low Prevalence and Complex Diseases of the Heart-ERN GUARD-Heart, Via Valdoni 7 , Trieste, CAP 34149 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2700-8478","authenticated-orcid":false,"given":"Gianfranco","family":"Sinagra","sequence":"additional","affiliation":[{"name":"Center for Diagnosis and Treatment of Cardiomyopathies, Cardiovascular Department, Azienda Sanitaria Universitaria Giuliano-Isontina (ASUGI) and University of Trieste , Via P. Valdoni 7, Trieste 34100 ,","place":["Italy"]},{"name":"European Reference Network for Rare, Low Prevalence and Complex Diseases of the Heart-ERN GUARD-Heart, Via Valdoni 7 , Trieste, CAP 34149 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1022-3131","authenticated-orcid":false,"given":"Marco","family":"Merlo","sequence":"additional","affiliation":[{"name":"Center for Diagnosis and Treatment of Cardiomyopathies, Cardiovascular Department, Azienda Sanitaria Universitaria Giuliano-Isontina (ASUGI) and University of Trieste , Via P. Valdoni 7, Trieste 34100 ,","place":["Italy"]},{"name":"European Reference Network for Rare, Low Prevalence and Complex Diseases of the Heart-ERN GUARD-Heart, Via Valdoni 7 , Trieste, CAP 34149 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,13]]},"reference":[{"key":"2026071313205997200_xuag200-B1","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"2026071313205997200_xuag200-B2","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa2409134","article-title":"Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy","volume":"392","author":"Fontana","year":"2024","journal-title":"N Engl J Med"},{"key":"2026071313205997200_xuag200-B3","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis","volume":"385","author":"Gillmore","year":"2021","journal-title":"N Engl J Med"},{"key":"2026071313205997200_xuag200-B4","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1161\/CIRCRESAHA.121.318187","article-title":"Pathophysiology and therapeutic approaches to cardiac amyloidosis","volume":"128","author":"Griffin","year":"2021","journal-title":"Circ Res"},{"key":"2026071313205997200_xuag200-B5","doi-asserted-by":"publisher","first-page":"6221","DOI":"10.1038\/s41467-024-50231-1","article-title":"Determinants of transthyretin levels and their association with adverse clinical outcomes among UK biobank participants","volume":"15","author":"Shetty","year":"2024","journal-title":"Nat Commun"},{"key":"2026071313205997200_xuag200-B6","doi-asserted-by":"publisher","first-page":"2979","DOI":"10.1002\/ejhf.70077","article-title":"Left ventricular transthyretin amyloid load and apical sparing in patients with newly confirmed transthyretin amyloid cardiomyopathy","volume":"27","author":"Krammer","year":"2025","journal-title":"Eur J Heart Fail"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjhf\/advance-article-pdf\/doi\/10.1093\/ejhf\/xuag200\/68765874\/xuag200.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/advance-article-pdf\/doi\/10.1093\/ejhf\/xuag200\/68765874\/xuag200.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T17:21:07Z","timestamp":1783963267000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/advance-article\/doi\/10.1093\/ejhf\/xuag200\/8733433"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,13]]},"references-count":6,"URL":"https:\/\/doi.org\/10.1093\/ejhf\/xuag200","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,13]]},"article-number":"xuag200"}}